News

Public · Published

TXO: Derivative losses drove a 45% Q3 revenue decline and a $32.1 million net loss

TXO reported that third-quarter revenue fell 45% year over year to $55.1 million, while derivative losses drove a $32.1 million net loss. Operating cash flow for the first nine months rose to $116.2 million, and 2026 capital spending guidance remained $90–$95 million.

Published:

Updated:

What happened

TXO reported that third-quarter revenue fell 45% year over year to $55.1 million, while derivative losses drove a $32.1 million net loss. Operating cash flow for the first nine months rose to $116.2 million, and 2026 capital spending guidance remained $90–$95 million.

Confirmed

Global impact / market context

The figures show weaker quarterly sales and a net loss alongside higher cash generated from operations over nine months. If derivative losses continue, they could weigh on reported results; meanwhile, the stated 2026 spending range signals a planned use of funds that could limit cash available for other needs.

Analyst inference

The article provides no share-price response, peer comparison, or explanation of the derivative positions, so it does not establish whether the results were better or worse than investors expected. The contrast between the quarterly loss and nine-month cash flow is relevant, but not enough to infer valuation or financial resilience.

Analyst inference

What to watch

  1. Future results may clarify whether derivative losses persist and how much they contribute to reported earnings, helping distinguish trading-related swings from changes in the underlying business. Analyst inference
  2. Compare subsequent operating cash flow with the 2026 capital spending range of $90–$95 million; the difference indicates how much internally generated cash may remain for other uses. Analyst inference
  3. Further detail on the causes of the 45% revenue decline and whether sales recover matters because sustained weakness could reduce the cash TXO generates from operations. Analyst inference

Evidence

  • Original source link unavailable